Friday, April 25, 2025 2:35:46 PM
An excerpt from Post 676902, 3/7/2024
DCVax’s mechanism of action leverages the immune system and therefore is intuitive to doctors
A. All antigens, information
- DCVax uses actual tumor lysate and importantly presents hundreds of DIFFERENT tumor antigens to the immune system
- Other drugs don’t
B. Efficacy, holistic approach
- Diversity in weapons: T cells, B cells, and antibodies
- Diversity in targets: activates unique cytotoxic T cells, helper T cells, B cells, and antibodies to target each different tumor antigen
- Robust immune memory: after killing the cancer, some T cells and B cells will become immune memory cells and remain
- Other drugs don’t
C. Naturally is not toxic
- Immature T cells and B cells travel thru the thymus and spleen. This process naturally screens out and destroys the self-reactive (autoimmune, toxicity) immune cells.
- Other drugs don't
D. Renaissance in how cancer is treated
- Today doctors have a “drug” that does not cure and must balance efficacy against toxicity
- Tomorrow doctors will have a DCVax “vaccine”, so their focus can then include optimizing a total therapy, including quality of life
The prospect of cancer cure is what all cancer patients desire most
A. DCVax as a vaccine
- Creating a more robust immune memory equates to cure and prevention
- Highly efficacious, non-toxic profile
- Other drugs are not
B. DCVax may possibly vaccinate against Second Primary Cancers
- 19% of cancer patients get a second cancer sometime in their life (unrelated to their first cancer). https://pubmed.ncbi.nlm.nih.gov/24857148/
- Dr. Bosch made this interesting point. Many of the tumor antigens found on the GBM tumor lysate were also the same tumor antigens found in other cancers
- Hypothesis is a DCVax enhanced immune memory can protect against other cancers, especially for those with genetic or family predisposition to a certain cancer.
- Other drugs don't
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Marijuana Breath Test Featured on the Cover of AlcoPro's 2026 Product Catalog • Jan 22, 2026 8:52 AM
Metavesco Congratulates DeFi Dev Corp on Becoming the Second Publicly Traded Company to Launch a Memecoin • MVCO • Jan 22, 2026 6:04 PM
Rainmaker Worldwide Strengthens North American Growth Pipeline With Affiliate Partnership Supporting Ontario's Housing Expansion • RAKR • Jan 22, 2026 10:19 AM
From Permits to Gold Pour: Why Readiness Matters • LFLR • Jan 22, 2026 9:00 AM
Envirotech Vehicles Reaffirms Momentum With AZIO AI and Provides Update on Nasdaq Compliance Process • EVTV • Jan 21, 2026 1:25 PM
Rainmaker Worldwide Expands U.S. Operations With ATMOCELL 5K and R/OCell® Deployments in the Permian Basin • RAKR • Jan 20, 2026 11:15 AM
